AroCell AB (publ)
Interim report for period 1 January - 31 March 2017
- Net sales were 56 (0) KSEK
- Loss after financial items was - 4,225 (- 2,842) KSEK
- Earnings per share were -0.15 (-0.10) SEK
- Cash flow from operating activities was -4,898 (-1,272) KSEK
- Cash flow from investing activities was 0 (-3,220) KSEK
This information is information that AroCell is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through Jan Stålemark, at 08:25 CET on 11 May 2017.
About AroCell
AroCell AB (AROC) is a Swedish company that develops standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell's new technology is based on patented methods to measure TK1 protein levels, which provide valuable information about the speed of cell turnover. A tumor has high cell turnover (speed of cell division and cell death) and as a result TK1 can be detected in the blood with a simple laboratory test, called TK 210 ELISA. The test provides valuable clinical information for prognosis and optimization of treatment strategy. The test may also be used for monitoring disease relapse. AroCell (AROC) is listed at Nasdaq First North and has about 2,600 shareholders. For more information, please see www.arocell.com. Redeye AB is AroCell:s Certified Adviser.
Significant events during the reporting period
- A scientific poster showing the correlation between TK 210 ELISA and Prostate Health Index (PHI) was accepted by AARC, American Association of Cancer Research.
- AroCell participated at the World Biomarker Congress in Manchester, UK in February.
- A webinar entitled "Improved Monitoring of Tumor Growth with a Novel Serum Proliferation Biomarker" was held on March 23rd, with 135 participants from both industry and academia.
Significant events after the reporting period
- AroCell attended the AACR congress in Washington, DC together with its distribution partner Eagle Biosciences.
- The Biomarker and World Congress in Philadelphia on May 2-4.
Comments by CEO Jan Stålemark